Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection

Drugs. 2005;65(3):413-32. doi: 10.2165/00003495-200565030-00006.

Abstract

Tenofovir disoproxil fumarate (tenofovir DF; Viread), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300 mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.

Publication types

  • Review

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / metabolism
  • Adenine / pharmacokinetics
  • Adenine / therapeutic use*
  • Area Under Curve
  • Biological Availability
  • Double-Blind Method
  • Drug Interactions
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • Half-Life
  • Humans
  • Metabolic Clearance Rate
  • Organophosphonates / metabolism
  • Organophosphonates / pharmacokinetics
  • Organophosphonates / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Tenofovir
  • Tissue Distribution

Substances

  • Organophosphonates
  • Tenofovir
  • Adenine